Literature DB >> 12166353

Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients.

C S Liau1, K L Chien, C L Chao, T M Lee.   

Abstract

The efficacy and safety profiles of barnidipine in the treatment of hypertension were evaluated in an open parallel-group study. Fifty-nine Chinese patients with mild-to-moderate essential hypertension were randomized to receive either barnidipine or felodipine (5 mg once daily, titrated to 10 mg or 15 mg once daily, as indicated) for 12 weeks. Both drugs reduced blood pressures significantly with > or = 68% of cases obtaining marked or moderate blood pressure reduction. Mean reductions in systolic and diastolic blood pressure for barnidipine treatment were 23.7 +/- 13.5 mmHg and 12.7 +/- 7.9 mmHg, and for felodipine, 24.3 +/- 18.4 mmHg and 14.5 +/- 10.0 mmHg, respectively. There was no significant difference between these two drugs in anti-hypertensive effect, heart rate, laboratory measurements or incidence of adverse events. The only difference was that more patients taking felodipine experienced palpitations. We conclude that barnidipine has similar efficacy and a similar safety profile to felodipine in the treatment of mild-to-moderate essential hypertension in Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12166353     DOI: 10.1177/147323000203000317

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  2 in total

1.  Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.

Authors:  Robert Lins; Yves Haerden; Caroline de Vries
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-03

2.  Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study.

Authors:  Giuseppe Rossetti; Samuele Pizzocri; Francesco Brasca; Marta Pozzi; Laura M Beltrami; Giovanni B Bolla; Roberta Famiani; Barbara Caimi; Stefano Omboni; Fabio Magrini; Stefano Carugo
Journal:  Curr Ther Res Clin Exp       Date:  2008-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.